Assertio Holdings, Inc. completed its merger with Zydus Worldwide DMCC on June 16, 2026, becoming a wholly owned subsidiary of the parent company. Following a tender offer that saw 4,286,488 shares (approximately 66.32% of outstanding stock) validly tendered, the company's common stock will be delisted from the Nasdaq. Shareholders received $23.50 per share in cash. The merger also triggered a fundamental change regarding the company's $40,000,000 aggregate principal amount of 6.50% Convertible Senior Notes due 2027, allowing noteholders to require a cash repurchase at 100% of the principal amount plus accrued interest. Assertio Holdings, Inc. is a pharmaceutical company.